期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (7)
Background Inflammatory bowel disease (IBD) services have been particularly affected by the Covid-19 pandemic. Delays in referral to secondary care an......
期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (6)
Background FODMAPs produce similar small bowel water and colonic gas in patients with irritable bowel syndrome (IBS) and healthy controls (HCs), despi......
期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (6)
Background Due to limited research on the natural history of indefinite for dysplasia (IND) and low-grade dysplasia (LGD) in inflammatory bowel diseas......
期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (10)
Background Some drugs for irritable bowel syndrome (IBS) have serious side effects. Aims To examine the willingness of individuals with IBS to accept ......
期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 55 (7)
Background Retrospective studies report that visualisation of the liver may be severely limited using ultrasound (US), potentially contributing to dim......
期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 56 (4)
Background Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (H......
期刊： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022; 56 (4)
Background Chicago Classification version 4.0 (CCv4.0) introduced stringent diagnostic criteria for oesophagogastric junction outflow obstruction (EGJ......
